Squarepoint
DNA icon

Squarepoint’s Ginkgo Bioworks DNA Stock Holding History

Squarepoint’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,013
Closed -$93.4K – 4182
2024
Q1 		$93.4K Buy
+2,013
New +$104K ﹤0.01% 3809

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's DNA Position: Q1 2026 in Review

Squarepoint reduced its Ginkgo Bioworks (DNA) stake by 72% in Q1 2026, selling an estimated $1.18M and leaving 54,930 shares worth $337K. The position accounts for ﹤0.01% of the portfolio, ranked #3620.

Squarepoint first reported a position in DNA in Q1 2022 and has held it in 11 quarters since. The position peaked at $1.94M in Q1 2023. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Squarepoint held 54,930 shares of Ginkgo Bioworks worth $337K as of Q1 2026.
  • Squarepoint sold 141,890 Ginkgo Bioworks shares in Q1 2026, an estimated $1.18M.
  • Ginkgo Bioworks made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3620 holding.
  • Squarepoint first reported a position in Ginkgo Bioworks in Q1 2022 and has held it in 11 quarters since.
  • Squarepoint's Ginkgo Bioworks position peaked at $1.94M in Q1 2023.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.